Cell Cycle / Checkpoint Control
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #9285S | 100 μL | 57,000 | |
|
| #9285P | 40 μL for Custom Sampler Kit |  Custom Antibody Sampler Kitの構成品を選択できます。
5本以上を選択し、ページ右上のCartから製品確定書を発行してください。
尚、構成品の単品販売は致しておりません。 | |
シグナル伝達研究応援キャンペーン プレゼント *Pサイズのみ
p53抗体製品一覧
9285 の推奨プロトコール
最適な結果を得るために:Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。
推奨プロトコールはCST社内試験の徹底的なバリデーションに基づいて作成されておりますので、正確かつ再現性の高い結果が得られます。
注:各製品に最適化されたプロトコールをリンクしています。
| | |
-
9285:
-
Immunoprecipitation
Western Blotting
| 用途 (希釈倍率) | |
| ウェスタンブロッティング (1:1,000)、免疫沈降 (1:100)、免疫細胞染色 (ABC法) (1:1,000) |
| 特異性・感度 | |
| 内在性レベルのSer6 がリン酸化されたp53 タンパク質を検出します。他の部位がリン酸化されたp53 タンパク質とは交差しません。 |
| 使用抗原 | |
| ヒトのp53 タンパク質のSer6 周辺領域 (合成リン酸化ペプチド) |
| ※括弧付きの動物種は、配列が100%相同であるため反応すると推定されます。 |
Western Blotting

Western blot analysis of extracts from COS cells treated with UV or MMS for the indicated times, using Phospho-p53 (Ser6) Antibody (upper) or p53 Antibody #9282 (lower).
Western Blotting

Western blot analysis of a p53 fusion protein, untreated or phosphorylated by CK1 or CK2, using Phospho-p53 (Ser6) Antibody (upper) or p53 Antibody #9282 (lower).
IC-ABC

Immunocytochemical analysis of COS cells, untreated or UV-treated, using Phospho-p53 (Ser6) Antibody.
The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis (1). p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro (2,3). DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2 (4). MDM2 inhibits p53 accumulation by targeting it for ubiquitination and proteasomal degradation (5,6). p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage (4,7). Chk2 and Chk1 can phosphorylate p53 at Ser20, enhancing its tetramerization, stability, and activity (8,9). p53 is phosphorylated at Ser392 in vivo (10,11) and by CAK in vitro (11). Phosphorylation of p53 at Ser392 is increased in human tumors (12) and has been reported to influence the growth suppressor function, DNA binding, and transcriptional activation of p53 (10,13,14). p53 is phosphorylated at Ser6 and Ser9 by CK1δ and CK1ε both in vitro and in vivo (13,15). Phosphorylation of p53 at Ser46 regulates the ability of p53 to induce apoptosis (16). Acetylation of p53 is mediated by p300 and CBP acetyltransferases. Inhibition of deacetylation suppressing MDM2 from recruiting HDAC1 complex by p19 (ARF) stabilizes p53. Acetylation appears to play a positive role in the accumulation of p53 protein in stress response (17). Following DNA damage, human p53 becomes acetylated at Lys382 (Lys379 in mouse) in vivo to enhance p53-DNA binding (18). Deacetylation of p53 occurs through interaction with the SIRT1 protein, a deacetylase that may be involved in cellular aging and the DNA damage response (19).
-
Levine, A.J. (1997) Cell 88, 323-331.
-
Meek, D.W. (1994) Semin. Cancer Biol. 5, 203-210.
-
Milczarek, G.J. et al. (1997) Life Sci. 60, 1-11.
-
Shieh, S.Y. et al. (1997) Cell 91, 325-334.
-
Chehab, N.H. et al. (1999) Proc. Natl. Acad. Sci. USA 96, 13777-13782.
-
Honda, R. et al. (1997) FEBS Lett. 420, 25-27.
-
Tibbetts, R.S. et al. (1999) Genes Dev. 13, 152-157.
-
Shieh, S.Y. et al. (1999) EMBO J. 18, 1815-1823.
-
Hirao, A. et al. (2000) Science 287, 1824-1827.
-
Hao, M. et al. (1996) J. Biol. Chem. 271, 29380-29385.
-
Lu, H. et al. (1997) Mol. Cell. Biol. 17, 5923-5934.
-
Ullrich, S.J. et al. (1993) Proc. Natl. Acad. Sci. USA 90, 5954-5958.
-
Kohn, K.W. (1999) Mol. Biol. Cell 10, 2703-2734.
-
Lohrum, M. and Scheidtmann, K.H. (1996) Oncogene 13, 2527-2539.
-
Knippschild, U. et al. (1997) Oncogene 15, 1727-1736.
-
Oda, K. et al. (2000) Cell 102, 849-862.
-
Ito, A. et al. (2001) EMBO J. 20, 1331-1340.
-
Sakaguchi, K. et al. (1998) Genes Dev. 12, 2831-2841.
-
Solomon, J.M. et al. (2006) Mol. Cell. Biol. 26, 28-38.